Alice T. Shaw, MD, PhD
Resistance mechanisms are among the primary challenges facing researchers seeking to enhance outcomes for patients with non–small cell lung cancer (NSCLC) whose tumors harbor ALK
rearrangements, according to Alice T. Shaw, MD, PhD.
In less than a decade, this aberration in NSCLC has gone from a little-understood molecular subset to a robust area of development with 4 FDA-approved drugs and additional novel agents under study. Shaw, whose work has been instrumental in defining and shaping the field, said moving more potent ALK inhibitors into the frontline setting and focusing on combination approaches are among the key strategies currently being explored.
“Overall, the constant cycle of response– resistance to each line of ALK inhibitor therapy seems to foster increasing tumor heterogeneity and a greater propensity to develop ALK-independent mechanisms of resistance,” Shaw said in an interview with OncLive
... to read the full story